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Disease Systems Analysis of Bone Mineral Density and
Bone Turnover Markers in Response to Alendronate,
Placebo, and Washout in Postmenopausal Women
J Berkhout1,2,3*, JA Stone4, KM Verhamme1, M Danhof2,3 and TM Post2,3
A previously established mechanism-based disease systems model for osteoporosis that is based on a mathematically
reduced version of a model describing the interactions between osteoclast (bone removing) and osteoblast (bone forming)
cells in bone remodeling has been applied to clinical data from women (n5 1,379) receiving different doses and treatment
regimens of alendronate, placebo, and washout. The changes in the biomarkers, plasma bone-specific alkaline phosphatase
activity (BSAP), urinary N-telopeptide (NTX), lumbar spine bone mineral density (BMD), and total hip BMD, were linked to the
underlying mechanistic core of the model. The final model gave an accurate description of all four biomarkers for the different
treatments. Simulations were used to visualize the dynamics of the underlying network and the natural disease progression
upon alendronate treatment and discontinuation. These results complement the previous applications of this mechanism-
based disease systems model to data from various treatments for osteoporosis.
CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 656–664; doi:10.1002/psp4.12135; published online 21 November 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 A mechanism-based model describing osteoblast
and osteoclast activity was reduced in order to apply it
in a population approach. Previously, it has been shown
that the model reduction did not jeopardize the dynami-
cal properties of the model. The reduced model was
successfully applied to describe responses in different
populations of postmenopausal women receiving differ-
ent treatments (e.g., tibolone or calcium).
WHAT QUESTION DID THIS STUDY ADDRESS?
 Is the current mechanism-based model able to accu-
rately describe the disease progression in a new popu-
lation receiving various doses and treatment regimens
of alendronate? In other words, do the systems-related
structure and parameter values that were fixed in this
study allow for a description of a drug with a different
mode of action than that was used before?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 The model, with updated treatment functions, could
describe the dynamics of two fast bone turnover
markers (BSAP and NTX) and two slower markers
(BMD at lumbar spine and total hip) from 1,379 study
subjects divided over five different treatment arms to a
very good approximation, showing the strength of a
population systems pharmacology approach.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 The results of this study allow for a better mechanis-
tic understanding upon response to alendronate treat-
ment and its washout. Additionally, these results
complement the framework that is developed using this
reduced mechanism-based model and provide a prom-
ising tool for the use of future applications of different
treatments.
Mechanism-based models are based on underlying physiolog-
ical networks. A fundamental property of a mechanism-based
model is that it can be used under different circumstances
than those in studies on which the model was developed (i.e.,
different drugs, different patients, etc.). An example for post-
menopausal osteoporosis is the mechanism-based disease
model developed by Lemaire et al.1 Osteoporosis is a complex
systemic skeletal disease resulting from an imbalance
between bone resorption and bone formation. In women it is
largely caused by a gradual loss of endogenous estrogen pro-
duction during and following menopausal transition, which
leads to an increased activity of osteoclast compared to
osteoblasts, a subsequent loss of bone, and eventually an
increased fracture risk.2–5
The Lemaire model describes the interactions between
osteoclast (bone removing) and osteoblast (bone forming)
cells in bone remodeling. In its original form this model was
not suitable to be applied in conjunction with advanced sta-
tistical techniques such as nonlinear mixed effects modeling
(i.e., a population approach6). Therefore, Schmidt et al.,
mathematically reduced the original model and, importantly,
demonstrated that the model reduction did not jeopardize
the model dynamics. Next, the reduced model was applied
to clinical data from postmenopausal women receiving
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various doses of tibolone by Post et al.7 Recently, the
reduced model was applied to yet another clinical study
population to describe the time course of osteoporosis in
postmenopausal women receiving placebo.8
As there are usually no direct measures for the function-
ing of osteoblasts and osteoclasts available in clinical set-
tings, different short-term biomarkers are used as indirect
measures of their dynamics. Biomarkers for the activity of
osteoblasts and osteoclasts are plasma bone-specific alka-
line phosphatase (BSAP) and urinary N-telopeptide (NTX).
Additionally, bone mineral density (BMD) in lumbar spine
(LS) and total hip (TH) are primary clinical long-term bio-
markers in the model. When the changes in these markers
are linked to the underlying mechanism-based core of the
model (Figure 1), these markers provide information about
the different stages of the bone remodeling process, its
dynamics, as well as the impact of therapeutic interventions
on the progression of this disease.
In this study we applied the previously established
reduced mechanism-based disease model to clinical data
from postmenopausal women (n5 1,379) receiving: 1) 2.5
or 5 mg of alendronate for 4 years, 2) placebo, or 3) 2
years of 2.5 or 5 mg alendronate followed by 2 years of pla-
cebo. Alendronate is a representative of the bisphospho-
nates, which are potent antiresorptive agents. After
administration, alendronate binds to the bone mineral and
is then taken up by osteoclasts where it inhibits enzymes in
the cholesterol biosynthesis pathway, resulting, among oth-
er things, in apoptosis.9 As alendronate is incorporated into
bone, upon treatment discontinuation the bone surface is
still less prone to breakdown, which can result in an ongo-
ing slower breakdown of bone. Furthermore, alendronate
released by breakdown of alendronate-containing bone may
be distributed to resorption surfaces that were not previous-
ly exposed to the drug, where it will inhibit resorption in pro-
portion to its surface concentration. The doses and duration
of alendronate treatment are relatively low and short
(respectively), so the long-term posttreatment effects due to
recycling of alendronate in bone are probably minimal in
Early Postmenopausal Intervention Cohort (EPIC). So as a
practical point, resolution of effect in EPIC is due mainly to
drug on bone surfaces at the end of 2 years of treatment.
We use the model to describe the changes in BMD and
bone turnover markers in response to these various treat-
ments. By doing so we will obtain deeper insight in the
important dynamics involved in the disease progression
and the underlying changes of the system during onset and
offset of the alendronate treatment.
METHODS
Subject population and study design
Data were obtained from the EPIC study. This study was
designed to study the efficacy and safety of daily oral
alendronate treatment for prevention of postmenopausal
osteoporosis. EPIC compared various regimens involving
alendronate in doses of 2.5 or 5.0 mg per day with estro-
gen and with placebo. The study involved 1,609 postmeno-
pausal women who were—after a 2-week, single-blind,
placebo run-in period—randomly assigned in a double-blind
manner to receive alendronate (Merck & Co., Whitehouse
Station, NJ), placebo, or open-label estrogen-progestin.
The total study duration was 4 years. In the current analy-
sis, data from the subjects receiving treatment with
Figure 1 Schematic representation of the mechanism-based disease systems analysis model. Active osteoblast and osteoclast cells
and the indicated interactions form the mechanism-based core (shown in gray) of this model, which are linked to the biomarkers, NTX,
BSAP, LS-BMD, and TH-BMD as shown in the striped area. PTH, parathyroid hormone, TGF-b, transforming growth factor-b, OPG,
osteoprotegerin, RANK, receptor activator of NF-jB, RANKL, receptor activator of NF-jB ligand, Dr and Db represent the differentiation
rate of osteoblast progenitors and of responding osteoblasts, respectively, kB is the apoptosis rate of active osteoblasts, DC is the dif-
ferentiation rate of osteoclast precursors, and DA is the osteoclast apoptosis rate due to TGF-b. RANKL binds to RANK and promotes
osteoclast differentiation, while OPG inhibits this differentiation by binding RANKL. Upon differentiation, responding osteoblasts mature
to active osteoblasts, which, in turn, are responsible for bone formation. Figure adapted from Ref. 8.
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estrogen were not included. Women in the alendronate
groups received alendronate during the first 2 years of the
study. Treatment was then continued without change or
was discontinued and replaced with placebo for the last 2
years of the study (Figure 2). At baseline all participants
were between 45 and 59 years of age, at least 6 months
past menopause, in good general health, and had no clini-
cal or laboratory evidence of confounding systemic disease.
Four study centers (two in the US: Portland, Oregon, and
Honolulu, Hawaii; and two in Europe: Nottingham, UK, and
Copenhagen, Denmark) were involved in this trial. To
ensure that most women who entered the study did not yet
have osteoporosis, only 10% of the women enrolled at
each center were allowed to have a baseline BMD at the
spine (L1–L4) below 0.8 g/cm2, as measured by dual-
energy x-ray absorptiometry. All women adhered to therapy
(had taken at least 80% of the prescribed number of tab-
lets, confirmed by tablet count). Dietary calcium intake was
estimated at baseline and annually during the study on the
basis of a food-frequency questionnaire. Further details
about this study have been published elsewhere.8,10,11
Measurement of bone mineral density and biochemical
markers of bone turnover
BMD of lumbar spine (LS) and total hip (TH) (defined as
the femoral neck plus trochanter and intertrochanteric area)
was measured by dual-energy x-ray absorptiometry (model
2000, Hologic, Waltham, MA) twice at baseline and annual-
ly thereafter. Blood and morning second-void urine samples
were collected after an overnight fast at baseline and every
6 months thereafter. Bone resorption was estimated using
urine N-telopeptide crosslinks of type I collagen (NTX)
(Osteomark, Ostex, Seattle, WA) as a biomarker. NTX is
reported as nmol bone collagen equivalents (bce) and cor-
rected for creatinine excretion (nmol bce/mmol cr). Serum
level of bone-specific alkaline phosphatase (BSAP) was
measured at baseline and at months 6, 12, 24, 36, 42, and
48 in a random sample of 550 women to estimate bone for-
mation (Ostase, Hybritech, San Diego, CA). BSAP is
reported in ng/mL.
Mechanism-based disease systems analysis model
For a detailed description of the model, see Ref. 8. The
mechanism-based core of this model is governed by the
following equations that take osteoblast activity (B) relative
to its baseline activity, Bo (y5B/B0) and the osteoclast (C)
activity relative to its baseline activity, Co (z5C/C0):
dy
dt
5kB r zð Þ2yf g
dz
dt
5DA
1
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f tð Þ5e2k estrogen t (1c)
In this equation f(t), Pca, EALN represent disease progres-
sion, placebo, and alendronate treatment functions, respec-
tively. In Eq. 1a the following system-specific parameters
can be identified: zs, a constant in r(z) defined as Cs/C0
(Cs is the value of C for which approximately half of the
transforming growth factor beta (TGF-b) receptors are
occupied1); kB is the elimination rate constant of osteoblast;
kestrogen is the estrogen elimination rate constant; DA is the
osteoclast apoptosis rate constant and b is the status of
the disease at baseline. All subjects received treatment
with placebo, whereas alendronate was only received by
subjects in the alendronate treatment arms. Both treat-
ments started at the same time (tstart) and the effect of pla-
cebo was extensively discussed and described previously8:
PCa tð Þ5
1 for 0 < t < tstart
12Pmax 12e2kCa;onset t2tstartð Þ
   e2kCa;offset t2tstartð Þ for t > tstart
(
(2)
where Pmax is a measure for the calcium induced inhibition
of the RANK- RANKL-OPG through parathyroid hormone
(PTH).1,12,13 Treatment effects of alendronate could either
be due to stimulation of apoptosis of active osteoclast or by
inhibition of osteoclast activity.14 In the model alendronate
increases the apparent apoptosis of osteoclasts due to
direct stimulation of apoptosis:
EALN tð Þ5Imax; ALN ALNID501ALN (3a)
Figure 2 Treatment allocation and sample size by treatment
group and study year. Women were randomized to receive pla-
cebo, 2.5 or 5.0 mg alendronate once daily and numbers
enrolled are shown for each treatment group. Women in the
alendronate groups received alendronate during the first 2 years
of the study. Treatment was then continued without change or
was discontinued and replaced with placebo for the last 2 years
of the study. ALN, alendronate.
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ALN tð Þ5ALNmax3
0 for 0 < t < tstart
12e2kdrugon t2tstartð Þ for tstart < t < tend
12e2kdrugoff tend2tstartð Þ
   e2kdrugoff t2tendð Þ for tend < t < 1
8><
>:
(3b)
The factor Imax,ALN represents the maximum treatment
effect of alendronate and ID50 is the dose at which its half-
maximum effect is reached. kdrugon and kdrugoff are the rate
constants for onset and elimination of alendronate for the
effects on the core system.
The panels in Figure 3 show an illustration of the dynam-
ics of the placebo, alendronate treatment and disease pro-
gression function.
The link to the biomarkers is achieved using the following
equations:
dBSAP
dt
5BSAP0  11kBSAP;0
   yqBSAP (4a)
dNTX
dt
5NTX0  zqNTX (4b)
dLS BMD
dt
5kinLS  yqB2koutLS  zqC  LS BMD (4c)
dTH BMD
dt
5kinTH  yqB2koutTH  zqC  TH BMD (4d)
where “0” indicates baseline value. kBSAP;0 is a scaling
parameter to account for different units of BSAP reported
in different clinical studies.8 q is a positive transduction
parameter, which links relative changes in cell activity to
those in the corresponding bone turnover markers: qBSAP
and qNTX for BSAP and NTX, respectively, and qB and qC
for relative osteoblast and osteoclast activity, respectively.
kinLS(TH) is a zero-order production rate constant for LS-
BMD (TH-BMD), koutLS(TH) is the first-order degradation
rate constant for LS-BMD (TH-BMD).
Body composition is known to induce changes in bone
morphology.15 Body mass index (BMI) was incorporated as
a fraction of LS-BMD0 and TH-BMD0 using the median BMI
of 25.4 kg/m2.
In order to initialize the model at a healthy normal state
(z, y, and S51) individual time scales were normalized
using time-since-onset-of-menopause as the characteristic
time frame (see also Figure 2 in Ref. 8).
Data analysis
R16 was used for data management and plotting. The mod-
el was implemented in NONMEM, V7.3 (ICON Develop-
ment Solutions, Ellicott City, MD), using ADVAN-6 and
FOCE-I. Visual predictive check (VPC), using 500 simula-
tions, were generated using PsN.17 Pirana18 and Xpose19
were used for model management and for plotting and ana-
lyzing NONMEM output, respectively. Simulations of the
final model were performed with Mathematica V9.0.
Prior to all analysis, measures for bone turnover markers
and BMD were log-transformed. The variance of random
interindividual variability on parameters was modeled by an
exponential model:
Pi5Pp  egi (5)
where Pp is the population value for parameter P, Pi the val-
ue for this parameter for the ith individual, and gi is the
interindividual random deviation, which is assumed to be
normally distributed with mean 0 and variance x2. The
residual variability resulting from measurement error and
model misspecification was parameterized as standard
deviation. The difference between observed and individual
predicted concentrations was modeled as an additive error
on logarithmic transformed data by:
ln yobsð Þ5ln ypred
 
1eij (6)
where eij is the residual error, with mean 0 and variance r
2,
between the jth observation in the ith individual ln(yobs) and
its prediction ln(ypred).
A considerable amount of between-subject variability was
found for the baseline values of NTX and BSAP, possibly
indicating issues with fasting, measurement precision, or bio-
logical variation.13 Therefore, a second residual variability
term eij2 was included to account for extreme bone turnover
measures, those below the 1% and above the 99% quantile
of the population distribution of the respective marker:
ln yobsð Þ1eij11W  eij2 (7)
where W51, and W5 0 for measures above the 1% and
below the 99% quantile. This adjustment positively influ-
enced stability and parameter identifiability of the model
and allowed inclusion of all available data.
Figure 3 Treatment functions used in the model. For the duration of the clinical study of 4 years the placebo function is shown in the
left panel. The alendronate treatment function is shown in the middle panel for the subjects who continued with active treatment (solid
line) and for the switchers to placebo (dashed line). The right panel shows the disease progression function, in which 1 represents a
healthy status and 0 full disease.
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Throughout model development diagnostic and individual
plots were inspected and used together with the drop in
objective function to come to the final model.
RESULTS
Of the 1,609 women enrolled in the EPIC study,10 data
from 1,379 were used in this study (i.e., excluding estrogen
treatment group). Of these study subjects, the baseline
demographic characteristics, years since menopause, LS-
BMD, TH-BMD, BSAP, and NTX are shown in Table 1.
There were no significant differences between the treat-
ment groups at baseline.
Final disease systems analysis model
The changes in LS-BMD and TH-BMD were best described
using a nonlinear indirect response model (Eq. 4c,d), as pre-
viously described by others.20,21 The mechanism of action of
alendronate was included as an induction of the elimination
of osteoclasts cells and reflects the interference of alendro-
nate with the osteoclast functioning. Whether this is through
increased apoptosis or just a permanent dysfunction state
being created by alendronate cannot be ruled out from our
data. This parameterization was chosen upon inspection of
the mechanism of action and the time course profiles of the
bone turnover marker as presented by Greenspan et al.22
The parameter estimates and interindividual variability (IIV)
of the final model are presented in Table 2. All parameters
in the final model could be estimated with a good precision
(coefficient of variation well below 40%).
Visual predictive check
To test whether the final model is able to describe the average
trends and the variability in the observed data a visual predic-
tive check (VPC) was performed. Plots split by treatment group
for the markers NTX (degradation), BSAP (formation), LS-
BMD, and TH-BMD (integrated markers), are presented in Fig-
ure 4. The model adequately describes the biomarker data at
all dose levels as the 5th, 50th, and 95th percentiles of the real
data (red lines) overlap with the 5th, 50th, and 95th percentiles
of the simulated data (black lines) and lie within the respective
prediction intervals of the simulations (blue and red areas). Fur-
thermore, the 5th, 50th, and 95th percentiles of the model pre-
diction (black lines) follow that of the real data (red lines).
Upon treatment with alendronate a sharp decrease in
BSAP and NTX was observed, which remained low for the 4
years of treatment or returned towards the baseline values
for treatment discontinuation. Note, however, that the levels
were not yet back at their baseline values after 4 years since
the start of the study. Also interesting to note is the fact that
the return of the biomarkers towards baseline values upon
treatment discontinuation is slower than the onset after start
of treatment. This could be the result of multiple phenomena
occurring simultaneously: a return component that has simi-
lar kinetics as onset, but that only partially returns one to
baseline and a remaining return that is much slower, likely
influenced by the slow washout of the drug incorporated into
bone. Bisphosphonate within bone is inactive and the phar-
macologic activity is driven by the drug that is released from
the long-term bone depot through ongoing bone remodeling.
Furthermore, it can be seen that the onset of the effect on
NTX is more rapid than for BSAP. This difference leads to
the creation of a window, where the effect on bone formation
lags behind that of bone resorption. The effect of this win-
dow is observed in the LS-BMD and TH-BMD dynamics,
where during placebo treatment there is a decrease in BMD,
while during treatment with alendronate an increase in BMD
is observed that is proportional with dose. During years 3
and 4, for BMD a decrease in LS and TH is observed in par-
ticipants who switched from alendronate to placebo.
Overall, the VPC plots give an impression of the ability of
the disease system approach to provide a physiological
framework extracting the information available in multiple
markers, which operate on different timescales.
Simulations
In order to obtain deeper insight into the underlying model
dynamics responsible for the observed alendronate
response, simulations with the final model were performed.
Simulations were performed with the population parame-
ters, as shown in Table 2. We see (Figure 5) that upon
treatment with alendronate (solid lines) a sharp decline in
osteoclast activity followed by a decline in osteoblast activi-
ty. When treatment is discontinued after 2 years (dashed
lines), the activities of both cell types increase again. When
only placebo is given, an increase in activities of both cells
is observed (dotted lines). Changes in BMD are determined
by the relative activities of osteoclast and osteoblast cells.
To visualize this, a variable S5 z/y was introduced. Thus,
when S is smaller than 1 (green area), osteoblasts activity
(y) is bigger than osteoclast (z), and hence BMD will
increase. For all panels solid lines correspond to treatment
with 5 mg of alendronate, dotted lines to placebo, and the
dashed lines show the treatment arm that received 5 mg
alendronate for the first 2 years followed by 2 years of
placebo.
Table 1 Baseline demographic characteristics of the different treatment arms from the EPIC study.
Characteristic Placebo 2.5 mg 2.5 mg ﬁ placebo 5.0 mg 5.0 mg ﬁ placebo
Subjects, n 470 330 133 321 125
Mean age at baseline6SD, years 53.36 3.7 53.36 3.6 53.76 3.5 53.46 3.5 53.763.6
Mean BMI at baseline6SD, kg/m2 25.26 3.6 25.66 3.6 25.36 3.8 25.16 3.7 26.263.5
Mean time since menopause at baseline6SD, years 5.76 5.4 6.36 5.9 6.36 6.0 6.56 5.9 6.165.5
Mean LS-BMD at baseline6SD, g/cm2 0.946 0.12 0.936 0.12 0.946 0.14 0.956 0.13 0.9660.14
Mean TH-BMD at baseline6SD, g/cm2 0.856 0.11 0.846 0.11 0.836 0.12 0.856 0.12 0.8660.11
Mean BSAP at baseline6SD (ng/ml) 11.26 4.4 10.96 3.9 10.16 3.7 10.96 3.7 10.864.2
Mean NTX at baseline6SD, nmol bce/mmol cr 88.06 45.0 83.36 46.4 83.66 41.7 86.06 48.2 86.6647.2
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For the bone turnover markers, we observe a sharp and
rapid decrease in NTX (degradation marker) and slower
decrease in BSAP (formation marker). This results in an
increase in BMD at the lumbar spine (green) and total hip
(brown) that is around 2–3% compared to the baseline val-
ue. Please note that EPIC was intended as an osteoporosis
prevention trial; beyond the modest increase in BMD seen
with alendronate treatment, the drug is preventing further
loss in BMD as seen with only placebo treatment. Interest-
ingly, this difference in onset was also observed in the
description of the VPC results. An advantage of simulations
is a continuous response, whereas in the available clinical
data the first measurement after treatment was only after 6
(NTX) or 12 months (BSAP). From the simulations it was
observed that NTX is at its lowest value within 1 month,
whereas the minimal level of BSAP is obtained around 6
months. This compares to previously published data where
NTX reaches it maximum within 2 to 4 weeks.23
When treatment is switched to placebo after 2 years, the
activity of osteoblast, osteoclast, and levels of NTX and BSAP
Table 2 Population parameter estimates of the final model.
Parameter (unit) Description Value (%CV)
System related parameters
zs (fraction) Constant in r(z) 0.659 (fixed)
kB (day
21) Elimination rate constant of osteoblast 0.0109 (fixed)
kestrogen (day
21) Estrogen elimination rate constant 0.00763 (fixed)
DA (day
21) Osteoclast apoptosis rate constant 1 (fixed)
b (%) Status of the disease process at baseline 1 (fixed)
Placebo related parameters
kCa,onset (day
21) Calcium elimination rate constant for onset 0.000304 (8.6)
KCa,offset (day
21) Calcium elimination rate constant for offset 0.000269 (16.9)
Treatment related parameters
Imax,ALN (-) Maximum alendronate effect 0.841 (3.6)
ALNmax (mg) Maximum alendronate exposure 5.0 (fixed)
ID50 (mg) The dose at which its half-maximum effect is reached 6.05 (38.5)
kdrugon (day
21) Alendronate onset rate constant 0.132 (35.6)
kdrugoff (day
21) Alendronate elimination rate constant 0.0285 (21.2)
Transducer function bone turnover markers
BSAP0 (U/L) BSAP baseline value 97.4 (fixed)
kBSAP0 (-) BSAP baseline scaling parameter 20.92 (0.2)
NTX0 (nmol bce/mmol cr) NTX baseline value 30.0 (4.2)
qBSAP (-) BSAP transduction parameter 1.45 (7.4)
qNTX (-) NTX transduction parameter 1.22 (6.0)
Transducer function bone mineral density
kin,ls (mg/day) Zero-order production rate constant for LS-BMD 0.212 (11.2)
LS-BMD0 (g/cm
2) LS-BMD baseline value 1.02 (0.5)
BMI-LS-BMD0 fraction (-) BMI fraction of LS-BMD baseline 0.0102 (9.6)
kin,th (mg/day) Zero-order production rate constant for TH-BMD 0.139 (11.4)
TH-BMD0 (g/cm
2) TH-BMD baseline value 0.91 (0.5)
BMI-TH-BMD0 fraction (-) BMI fraction of TH-BMD baseline 0.0164 (6.0)
qB (-) Osteoblast transduction parameter 1.67 (16.3)
qC (-) Osteoclast transduction parameter 0.784 (12.6)
Inter individual variability
IIV NTX0 (%) IVV NTX baseline 36.2 (2.6)
IIV BSAP0 (%) IVV BSAP baseline 28.9 (3.7)
corr NTX0-BSAP0 (-) IVV correlation NTX-BSAP baseline 0.47 (10.4)
IIV BMDLS,0 (%) IVV LS-BMD baseline 12.5 (2.1)
IIV BMDTH,0 (%) IVV TH-BMD baseline 12.2 (1.9)
corr BMDLS,0-TH,0 (-) IVV correlation LS-TH-BMD baseline 0.65 (1.5)
Residual variability
eBSAP (SD) Residual variability BSAP 0.185 (2.7)
eBSAP,extremes (SD) Residual variability BSAP extremes 0.505 (10.1)
eNTX (SD) Residual variability NTX 0.321 (1.1)
eNTX, extremes (SD) Residual variability NTX extremes 0.281 (7.2)
eLS (SD) Residual variability LS-BMD 0.024 (1.5)
eTH (SD) Residual variability LS-BMD 0.019 (1.4)
Disease Systems Analysis of Bone Mineral Density
Berkhout et al.
661
www.wileyonlinelibrary/psp4
change in the direction of their pretreatment values, leading to
a decrease in BMD. This decrease is smaller compared to the
subjects receiving placebo treatment for 4 years. Four years of
treatment with placebo results in a continuous decline in BMD
that is on the order of 1–2% below their baseline value.10
DISCUSSION
In this study we applied a mechanism-based disease sys-
tems analysis to clinical trial data from postmenopausal
women who were treated with various doses of alendronate,
placebo, or a combination of active treatment followed by
placebo. In line with results from earlier studies, 4 years of
alendronate treatment prevented postmenopausal bone loss
at the lumbar spine and total hip and was more effective
than 2 years of alendronate treatment followed by 2 years of
placebo. In addition, increased BMD at these two sites was
maintained in women who received alendronate for 4
years.10,11,24 The advantage of the mechanism-based model
is that these observations can be linked to the underlying
changes in activities of osteoblast and osteoclast cells. The
simulations support that NTX and BSAP closely follow the
dynamics of osteoclasts and osteoblasts, and their combined
activity, S5 z/y, determines changes in BMD through the
nonlinear indirect response model of Eq. (4c,d). Since the
ratio S drops well below unity for a longer period of time dur-
ing treatment, BMD increases.
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Figure 4 Visual predictive check (VPC) plots. The columns show the different treatment groups, from left to right: placebo, 2 years
2.5 mg alendronate followed by 2 years placebo, 2.5 mg alendronate, 2 years 5.0 mg alendronate followed by 2 years placebo, 5.0 mg
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Our simulations further suggest that 4 years of treatment
with alendronate had a disease-modifying (i.e., affecting the
disease progression rate) effect on BMD. While the
increase in BMD after 2 years of alendronate treatment
decreases when treatment was switched to placebo for the
last 2 years of the study, it did not decrease completely to
baseline levels at year 4. This suggests a residual effect of
previous treatment with alendronate, which may be caused
in part because alendronate is retained in the skeleton.
Also, alendronate had a symptomatic effect25 on the bone
turnover markers, since these levels almost return to their
pretreatment levels (Figures 4 and 5), with the residual
effect of incorporation of alendronate into the bone still visi-
ble. Furthermore, our analysis indicates that changes in
BMD in total hip are slower (kin,th5 0.139 mg/day) than
those in lumbar spine (kin,ls5 0.212 mg/day). These findings
are in line with the underlying bone physiology as trabecular
bone, which turns over faster than cortical bone, is present
in larger quantities in the spine compared to the hip.
We were able to estimate all parameters with good preci-
sion (all coefficients of variation (CV) <38.5%). However,
for complex mathematical models caution should be taken
with interpretation of these precision measures. For our
model this was observed for the estimated value for the
ID50 estimate for alendronate (6.05 mg). Despite a low CV,
this estimate falls above the dose range (2.5–5 mg) avail-
able in the dataset. Preconditioning methods, as recently
proposed,26 can be informative for such identifiability
issues. Dose-ranging studies of alendronate for treatment
of osteoporosis identified a similar response at 10 and
20 mg daily,27 suggesting that the estimate from this analy-
sis may be high. This could be due to limitations in the
available dataset as well as potentially complexities in the
dynamics of washout and switch to placebo treatment.
In comparison to the BMD equation that was used previ-
ously,8 we obtained the best description of this dataset
when a nonlinear BMD equation was used (Eq. 4c,d). This
is also in line with results from others.21 The nonlinear
response in BMD is best visible from our model simula-
tions. Whether the changes in BMD in this study population
are truly nonlinear cannot be determined with the 1-year
measurement frequency over this 4-year period.
This model has recently been applied to postmenopausal
women receiving various doses of tibolone.7 The mechanis-
tic nature of this population model makes it possible to
evaluate the effect of other drugs with different mechanisms
and modes of action such as alendronate. This also shows
the strength of a disease systems analysis25 model; the
core remains the same and the markers that supply the
required information on the system can differ or come from
different treatments, which is in contrast to empirical mod-
els where (single) marker(s) are directly linked. On the oth-
er side of the model spectrum, systems pharmacology
models, integrate different signaling networks and organs to
describe calcium homeostasis and bone remodeling.12,21
Recently, such a systems pharmacology model was used
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by the US Food and Drug Administration to evaluate the
appropriateness of a proposed dosing regimen for a new
biologic.28 Due to their inherent complexity, the establish-
ment of completely systems pharmacology models within a
population framework is hindered by the inability to identify
and estimate the pertinent model parameters.29
Despite the large number of subjects in this study and the
crossover design, the initial dynamics of the systems could
not be identified from these data. Probably this is due to the
lack of data during the early treatment period. We anticipate,
therefore, that with more data points available right after onset
of treatment the system-specific parameter, Da, i.e., osteo-
clast apoptosis rate constant, could be identifiable as well.
In conclusion, we applied a previously established
mechanism-based model to a new set of clinical data from
postmenopausal women receiving alendronate, placebo, or
a combination of both (i.e., washout). We were able to iden-
tify the underlying changes in the bone remodeling network
upon continuation and discontinuation of alendronate treat-
ment. In addition, these results build upon the framework
obtained with this mechanism-based model: first, it has
been reduced,30 followed by the application to different
study populations receiving different treatments, including:
tibolone,7 placebo,8 and now alendronate.
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